Less than 10% of individuals eligible to benefit from obesity jabs including Wegovy have access to them, caution the global health agency as it releases its inaugural advice on the drugs.
Considering in excess of 1,000,000,000 people worldwide now classified as obese, it is urging broader and more equitable access to these injectable treatments.
Per forecasts, in excess of 2,000,000,000 will be living with obesity by 2030 if no action is taken.
"Our latest guidelines acknowledges that excess weight is a lifelong illness that can be managed with holistic and continuous treatment," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and supply-chain constraints are major barriers to universal availability to the injections that can aid individuals in losing substantial weight, notes the body.
GLP-1 Therapy Scarcity
Despite the current best projected case, the manufacturing of such drugs would only suffice for approximately 100 million people – fewer than 10% of those who need them, according to the health organization.
The guideline encourages nations and manufacturers to expand availability, by approaches such as licensing agreements.
A patent on the active ingredient – the core ingredient of the drug Wegovy – is scheduled to end in multiple nations in 2026.
How Weight-Loss Drugs Function
GLP-1 drugs replicate a biological compound to reduce digestion speed, reduce hunger and increase satiety so users eat less.
Patients usually begin shedding pounds after several weeks of commencing the once-weekly jabs.
Research indicates patients may regain a significant portion after a year of halting the medication, when their typical appetite come back.
To be above a healthy weight elevates your risk for contracting health problems, such as diabetes, heart disease, brain attack, and specific cancers.
Excess weight affects individuals in every country and was responsible for 3.7 million fatalities worldwide in 2024, according to the WHO.
